

3A4-H4
10A1-A6
11E10-B8
11E10-C3
Tau
pTau
2.0
1.5
1.0
0.5
0.0
1/10
1/100
1/1000
1/10000
1/100000
O.D.
Antibody Dilution

FIG. 1A



17G12-C11
19H6-F7
54C1-C3
37D3-H9
Tau
pTau
O.D.
Antibody Dilution
1/10
1/100
1/1000
1/10000
1/100000

FIG. 1B



54C1-H11
61E7-C4
29E6-B2
45H12-G5
Tau
pTau
O.D.
2.0
1.5
1.0
0.5
0.0
1/10
1/100
1/1000
1/10000
1/100000
Antibody Dilution

FIG. 1C



12A10-E8
14F5-D9
15C6-A7
19F8-B1
Tau
pTau
O.D.
2.0
1.5
1.0
0.5
0.0
1/100
1/400
1/1600
1/6400
Antibody Dilution

FIG. 1D



26C1-C8
52F6-F11
73H6-A8
123E9-A1
Tau
pTau
O.D.
2.0
1.5
1.0
0.5
0.0
1/100
1/400
1/1600
1/6400
Antibody Dilution

FIG. 1E



64B9-E11
63H3-B2
65B1-A2
127G7-A5
Tau
pTau
O.D.
Antibody Dilution
1/100
1/400
1/1600
1/6400

FIG. 1F



11E10-C3
61E7-C4
73H6-B8
3A4-H4
Monomers
Oligomers
O.D.
Biotinylated Tau (µg/ml)

FIG. 2A



19H6-F7
11E10-B8
10A1-A6
54C1-C3
O.D.
Monomers
Oligomers
Biotinylated Tau (µg/ml)
5.0000
2.5000
1.2500
0.6250
0.3125
0.1563
0.0781
0.0391
0.0195
0.0098
0.0049
0.0024
0.0012
0.0006
0.0003
0.0002
5.000
2.500
1.250
0.625
0.313
0.156
0.078
0.039

FIG. 2B



14F5-D9
19F8-B1
15C6-A7
26C1-C8
O.D.
Monomers
Oligomers
Biotinylated Tau (µg/ml)
5.000 2.500 1.250 0.625 0.313 0.156 0.078 0.039
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6

FIG. 2C



12A10-B6
- Monomers
Oligomers
O.D.
Biotinylated Tau (µg/ml)
123E9-A1
- Monomers
Oligomers
O.D.
Biotinylated Tau (µg/ml)
54C1-H11
- Monomers
Oligomers
O.D.
Biotinylated Tau (µg/ml)
37D3-H9
- Monomers
Oligomers
O.D.
Biotinylated Tau (µg/ml)

FIG. 2D



17G12-C11
52F6-F11
O.D.
Monomers
Oligomers
Biotinylated Tau (µg/ml)
5.000 2.500 1.250 0.625 0.313 0.156 0.078 0.039
0.0
0.5
1.0
1.5
2.0
2.5
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6

FIG. 2E



Blotted with: (Epitope):
37D3-H9 (Tau10-24)
94B2-C1 (Tau1-15)
125B11-H3 (Tau109-123)
AD Control
AD18
C25
AD24
C21
AD27
hTau Ladder
250
150
100
75
50
37
25
20
15
10
2N4R
2N3R
1N4R
1N3R
0N4R
0N3R

FIG. 3




FIG. 4A




FIG. 4B




FIG. 4C



150
130
110
90
70
50
30
10
-10
-1000
2000
5000
8000
11000
14000
17000

FIG. 5

hu37D3-H9.v5 hIgG4, t=0
80
70
60
50
40
30
20
10
0
-10
-500
0
500
1000
1500
2000
2500





hu37D3-H9.v5 hIgG4, t=2 Weeks
80
70
60
50
40
30
20
10
0
-10
-500
0
500
1000
1500
2000
2500

FIG. 6

FIG. 7


hu37D3-H9.v5
90
70
50
30
10
-10
-100
0
100
300
500
700
900


hu37D3-H9.v5 N28D
90
70
50
30
10
-10
-100
0
100
300
500
700
900



hu37D3-H9.v5 and hu37D3-H9.v5 N28D,
Mixed at a 1:1 Ratio
90
70
50
30
10
-10
-100
0
100
300
500
700
900

FIG. 8A

FIG. 8B

FIG. 8C

FIG. 8D

FIG. 8

FIG. 8A

Antibody	KD (nM)	Stability Index	Chi2 < 10% Rmax and Normalized Rmax (Pre-stress) > 0.1?	VL Residues at Selected Locations (Kabat Numbering)												SEQ ID:
				1	2	4	27D	27E	28	29	30	31	32	33	93	
Unstressed Control (mean, n=9)	**1.0**	**106%**	**Yes**	**E**	**D**	**L**	**H**	**S**	**N**	**G**	**N**	**T**	**Y**	**F**	**L**	350
hu37D3-H9.v5	0.9	73%	Yes	E	D	L	H	S	N	G	N	T	Y	F	L	351
hu37D3-H9.v5.1	4.0	72%	Yes	E	D	L	H	S	N	A	N	T	Y	F	L	352
hu37D3-H9.v5.2	10.9	97%	Yes	E	D	L	H	S	S	G	N	T	Y	F	L	353
hu37D3-H9.v5.3	73.2	70%	Yes	E	D	L	H	S	D	G	N	T	Y	F	L	354
hu37D3-H9.v5.4	36.1	78%	-	E	D	L	H	S	Q	G	N	T	Y	F	L	355
hu37D3-H9.v5.5	64.5	75%	-	E	D	L	H	S	E	G	N	T	Y	F	L	356
hu37D3-H9.v5.6	36.6	67%	-	E	D	L	H	S	A	G	N	T	Y	F	L	357
hu37D3-H9.v5.7	13.0	67%	Yes	E	D	L	H	S	N	G	D	T	Y	F	L	358
hu37D3-H9.v5.8	2.2	90%	Yes	E	D	L	H	S	N	G	Q	T	Y	F	L	359
hu37D3-H9.v5.9	5.3	95%	Yes	E	D	L	H	S	N	G	E	T	Y	F	L	360
hu37D3-H9.v5.10	4.7	78%	Yes	E	D	L	H	S	N	G	A	T	Y	F	L	361
hu37D3-H9.v5.11	97.7	71%	Yes	E	D	L	H	S	N	G	S	T	Y	F	L	362
hu37D3.v28	0.9	78%	Yes	D	D	L	H	S	N	G	N	T	Y	F	L	363
hu37D3.v28.A2	32.6	72%	Yes	D	D	L	H	S	N	G	N	T	Y	F	H	364
hu37D3.v28.A4	1.2	96%	Yes	D	D	L	H	S	N	G	N	T	Y	L	L	365
hu37D3.v28.A6	38.3	82%	Yes	D	D	L	H	S	N	G	N	T	Y	L	H	366
hu37D3.v28.A8	1.8	57%	Yes	D	D	M	H	S	N	G	N	T	Y	F	L	367

																								SEQ ID:
hu37D3.v28.A10	41.8	37%	Yes	D	D	M	H	S	N	G	N	T	Y	F	H									368
hu37D3.v28.A12	1.8	88%	Yes	D	D	M	H	S	N	G	N	T	Y	L	L									369
hu37D3.v28.A14	51.4	70%	Yes	D	D	M	H	S	N	G	N	T	Y	L	H									370
hu37D3.v28.A16	3.9	89%	Yes	D	V	L	H	S	N	G	N	T	Y	F	L									371
hu37D3.v28.A18	17.3	83%	Yes	D	V	L	H	S	N	G	N	T	Y	F	H									372
hu37D3.v28.A20	7.1	93%	Yes	D	V	L	H	S	N	G	N	T	Y	L	L									373
hu37D3.v28.A22	27.8	70%	Yes	D	V	L	H	S	N	G	N	T	Y	L	H									374
hu37D3.v28.A24	4.7	95%	Yes	D	V	M	H	S	N	G	N	T	Y	F	L									375
hu37D3.v28.A26	22.5	78%	Yes	D	V	M	H	S	N	G	N	T	Y	F	H									376
hu37D3.v28.A28	11.4	89%	Yes	D	V	M	H	S	N	G	N	T	Y	L	L									377
hu37D3.v28.A30	34.4	77%	-	D	V	M	H	S	N	G	N	T	Y	L	H									378
hu37D3.v28.B1	24.3	101%	Yes	D	D	L	H	S	I	G	N	T	F	F	L									379
hu37D3.v28.B2	31.8	83%	Yes	D	D	L	H	S	M	G	N	T	F	F	L									380
hu37D3.v28.B3	0.4	208%	-	D	D	L	H	S	Q	G	N	T	W	F	L									381
hu37D3.v28.B4	10.5	288%	-	D	D	L	H	S	Q	G	N	T	H	F	L									382
hu37D3.v28.B6	85.6	46%	Yes	D	D	L	H	S	D	G	N	T	R	F	L									383
hu37D3.v28.B7	4.1	607%	-	D	D	L	H	S	D	G	N	T	K	F	L									384
hu37D3.v28.B8	1.8	456%	-	D	D	L	H	S	E	G	N	T	R	F	L									385
hu37D3.v28.C1	1.4	77%	Yes	D	D	L	H	S	N	N	N	T	Y	F	L									386
hu37D3.v28.C2	9.6	75%	Yes	D	D	L	H	S	N	D	N	T	Y	F	L									387
hu37D3.v28.D1	5.7	73%	Yes	D	D	L	H	A	N	G	N	T	Y	F	L									388

FIG. 8B

Antibody	KD (nM)	Stability Index	Chi2 < 10% Rmax and Normalized Rmax (Pre-stress) > 0.1?	VL Residues at Selected Locations (Kabat Numbering)												SEQ ID:
				1	2	4	27D	27E	28	29	30	31	32	33	93	
Unstressed Control (mean, n=9)	**1.0**	**106%**	**Yes**	**E**	**D**	**L**	**H**	**S**	**N**	**G**	**N**	**T**	**Y**	**F**	**L**	389
hu37D3.v28.E1	20.1	46%	Yes	D	D	L	N	S	N	G	N	T	Y	F	L	390
hu37D3.v28.E2	22.5	28%	Yes	D	D	L	Q	S	N	G	N	T	Y	F	L	391
hu37D3.v28.E3	1.1	364%	-	D	D	L	D	S	D	G	N	T	Y	F	L	392
hu37D3.v28.F1	2.1	81%	Yes	D	D	L	H	S	N	T	N	T	Y	F	L	393
hu37D3.v28.F2	1.9	51%	Yes	D	D	L	H	T	N	G	N	T	Y	F	L	394
hu37D3.v28.F3	9.5	70%	Yes	D	D	L	H	T	N	A	N	T	Y	F	L	395
hu37D3.v28.51	35.6	74%	-	E	D	L	H	S	H	G	N	T	Y	F	L	396
hu37D3.v28.52	17.6	80%	Yes	E	D	L	H	S	K	G	N	T	Y	F	L	397
hu37D3.v28.53	22.9	76%	Yes	E	D	L	H	S	R	G	N	T	Y	F	L	398
hu37D3.v28.54	24.8	82%	Yes	E	D	L	H	S	L	G	N	T	Y	F	L	399
hu37D3.v28.55	2.6	82%	Yes	D	D	L	H	S	N	Q	N	T	Y	F	L	400
hu37D3.v28.56	5.4	76%	Yes	D	D	L	H	S	N	Y	N	T	Y	F	L	401
hu37D3.v28.57	4.4	88%	Yes	D	D	L	H	S	N	F	N	T	Y	F	L	402
hu37D3.v29.1	13.5	70%	Yes	E	D	L	H	S	N	G	D	T	Y	F	L	403
hu37D3.v29.2	2.6	88%	Yes	E	D	L	H	S	N	G	Q	T	Y	F	L	404
hu37D3.v29.3	5.6	93%	Yes	E	D	L	H	S	N	G	E	T	Y	F	L	405
hu37D3.v29.4	4.9	76%	Yes	E	D	L	H	S	N	G	A	T	Y	F	L	406
hu37D3.v29.5	1.4	64%	Yes	E	D	L	H	S	N	G	H	T	Y	F	L	407
hu37D3.v29.6	1.4	62%	Yes	E	D	L	H	S	N	G	K	T	Y	F	L	408
hu37D3.v29.7	4.6	90%	Yes	E	D	L	H	S	N	G	L	T	Y	F	L	409
hu37D3.v29.8	40.9	77%	-	E	D	L	H	S	N	A	D	T	Y	F	L	410
hu37D3.v29.9	7.3	86%	Yes	E	D	L	H	S	N	A	Q	T	Y	F	L	411
hu37D3.v29.10	17.4	100%	Yes	E	D	L	H	S	N	A	E	T	Y	F	L	412

FIG. 8C

																			SEQ ID:
hu37D3.v29.11	27.9	67%	Yes	E	D	L	H	S	N	A	A	T	Y	F	L				413
hu37D3.v29.12	7.0	50%	Yes	E	D	L	H	S	N	A	H	T	Y	F	L				414
hu37D3.v29.13	6.7	79%	Yes	E	D	L	H	S	N	A	K	T	Y	F	L				415
hu37D3.v29.14	22.0	92%	Yes	E	D	L	H	S	N	A	L	T	Y	F	L				416
hu37D3-H9.v30.1	23.5	87%	Yes	D	D	L	H	S	G	G	N	T	Y	F	L				417
hu37D3-H9.v30.2	4.2	96%	Yes	D	D	L	H	S	T	G	N	T	Y	F	L				418
hu37D3-H9.v30.3	38.1	83%	Yes	D	D	L	H	S	V	G	N	T	Y	F	L				419
hu37D3-H9.v30.4	22.0	87%	Yes	D	D	L	H	S	L	G	N	T	Y	F	L				420
hu37D3-H9.v30.5	29.1	80%	Yes	D	D	L	H	S	I	G	N	T	Y	F	L				421
hu37D3-H9.v30.6	19.1	270%	-	D	D	L	H	S	P	G	N	T	Y	F	L				422
hu37D3-H9.v30.7	34.9	93%	-	D	D	L	H	S	F	G	N	T	Y	F	L				423
hu37D3-H9.v30.8	31.4	105%	-	D	D	L	H	S	Y	G	N	T	Y	F	L				424
hu37D3-H9.v30.9	36.4	63%	-	D	D	L	H	S	H	G	N	T	Y	F	L				425
hu37D3-H9.v30.10	16.1	84%	Yes	D	D	L	H	S	K	G	N	T	Y	F	L				426
hu37D3-H9.v30.11	20.9	86%	Yes	D	D	L	H	S	R	G	N	T	Y	F	L				427
hu37D3-H9.v31.1	41.2	72%	-	D	D	L	H	S	N	A	G	T	Y	F	L				428
hu37D3-H9.v31.2	10.6	90%	Yes	D	D	L	H	S	N	A	V	T	Y	F	L				429
hu37D3-H9.v31.3	9.8	93%	Yes	D	D	L	H	S	N	A	I	T	Y	F	L				430
hu37D3-H9.v31.4	0.8	533%	-	D	D	L	H	S	N	A	P	T	Y	F	L				431
hu37D3-H9.v31.5	15.2	85%	Yes	D	D	L	H	S	N	A	F	T	Y	F	L				432
hu37D3-H9.v31.6	15.5	90%	Yes	D	D	L	H	S	N	A	Y	T	Y	F	L				433
hu37D3-H9.v31.7	6.9	83%	Yes	D	D	L	H	S	N	A	R	T	Y	F	L				434
hu37D3-H9.v31.8	10.9	78%	Yes	D	D	L	H	S	N	A	N	V	Y	F	L				435
hu37D3-H9.v31.9	7.5	81%	Yes	D	D	L	H	S	N	A	N	I	Y	F	L				436
hu37D3-H9.v31.10	5.5	261%	-	D	D	L	H	S	N	A	N	P	Y	F	L				437
hu37D3-H9.v31.11	22.7	126%	-	D	D	L	H	S	N	A	N	F	Y	F	L				438
hu37D3-H9.v31.12	41.6	99%	-	D	D	L	H	S	N	A	N	Y	Y	F	L				439
hu37D3-H9.v31.13	48.1	83%	-	D	D	L	H	S	N	A	N	N	Y	F	L				440
hu37D3-H9.v31.14	35.5	86%	-	D	D	L	H	S	N	A	N	R	Y	F	L				441

FIG. 8D



Heavy Chain
Light Chain
N28
G29
Y32
N30
T31
F33

FIG. 9



anti-Tau 37D3 mIgG2a (IV)
anti-Tau 37D3 mIgG2a (IP)
Antibody Concentration (µg/mL)
1000
100
10
1
0
10
20
30
Time (Day)

FIG. 10




FIG. 11




FIG. 12B




FIG. 12C



Left to right for each peptide:
ACI-54C1-H11
ACI-3A4-H4
ACI-19H6-F7
ACI-37D3-H9
94B2-C1
19F8-C11
89F4-A1
123E9-A1
O.D.
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
1-15
10-24
19-33
28-42
37-51
46-60

FIG. 12A




FIG. 13A




FIG. 13B



pTau 212/214 Hippocampus Integrated OD
200000
150000
100000
50000
0
Dose Effect
p<0.0001
Dose Effect
p<0.0011
gp120 - 30mg/kg
37D3 - 3mg/kg
37D3 - 10mg/kg
37D3 - 30mg/kg
37D3 DANG - 3mg/kg
37D3 DANG - 10mg/kg
37D3 DANG - 30mg/kg

FIG. 14



Native Tau Position 2
37D3 Epitope (2-24)
PRO364486.HU 1 MHHHHHHGENLYFQGSAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQ 50
PRO378546.CYNO 1 MHHHHHHGENLYFQGSAEPRQEFDVMEDHAGTYGLGDRKDQEGYTMLQDQ 50
PRO364486.HU 51 EGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAP 100
PRO378546.CYNO 51 EGDTDAGLKESPLQTPAEDGSEELGSETSDAKSTPTAEDVTAPLVDERAP 100
PRO364486.HU 101 GKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQARMVSKSKDGT 150
PRO378546.CYNO 101 GEQAAAQPHMEIPEGTTAEEAGIGDTPSLEDEAAGHVTQARMVSKSKDGT 150
PRO364486.HU 151 GSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSS 200
PRO378546.CYNO 151 GSDDKKAKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSS 200
PRO364486.HU 201 GEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKS 250
PRO378546.CYNO 201 GEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPAREPKKVAVVRTPPKS 250
PRO364486.HU 251 PSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLS 300
PRO378546.CYNO 251 PSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLS 300
PRO364486.HU 301 NVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGG 350
PRO378546.CYNO 301 NVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGG 350
PRO364486.HU 351 QVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAK 400
PRO378546.CYNO 351 QVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAK 400
PRO364486.HU 401 TDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSAS 450
PRO378546.CYNO 401 TDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSAS 450
PRO364486.HU 451 LAKQGL 456 SEQ ID NO: 1
PRO378546.CYNO 451 LAKQGL 456 SEQ ID NO: 3

FIG. 15



1000
100
10
1
Antibody Concentration (µg/mL)
94B2 10mg/kg (Generic)
94B2 10mg/kg (Specific)
0
10
20
30
Time (Day)

FIG. 16



1000
100
10
1
Antibody Concentration (µg/mL)
anti-Tau 125B11 Generic
anti-Tau 125B11 Specific
0
10
20
30
Time (Day)

FIG. 17

Light Chain Variable Region




FIG. 18




FIG. 19A




FIG. 19B



Plasma Antibody Concentration (µg/mL)
1000
100
50
40
30
20
10
1.0
0.8
0.6
0.4
0.2
-2
-3
-4
-5
Time (Day)
2000
1500
1000
500
0
Plasma Total Tau Concentration, Normalized to Baseline Elecsys
anti-gD hIgG4 - PD
hu37D3.v28.A4 hIgG4-S228P - PD
hu37D3.v28.A4 hIgG4-S228P.YTE - PD
anti-gD hIgG4 - PK
hu37D3.v28.A4 hIgG4-S228P - PK
hu37D3.v28.A4 hIgG4-S228P.YTE - PK

FIG. 20



hu37D3.v28.A4 hIgG4.S228P
2 Day
10 Day
Antibody Concentration (µg/g)
0.0
0.2
0.4
0.6
0.8
Cerebral Cortex - Superficial
Caudate Nucleus
Cerebral Cortex (Frontal) - Superficial
Cerebral Cortex - Superficial
Cerebral Cortex (Temporal) - Superficial
Globus Pallidus
Ventral Pallidum
Hippocampus
Pons-Dorsal
Pons-Ventral
Cerebellum
Cerebellum

FIG. 21A



hu37D3.v28.A4 hIgG4.S228P.YTE
▲2 Day
△10 Day
Antibody Concentration (µg/g)
0.0
0.2
0.4
0.6
0.8
Cerebral Cortex - Superficial
Caudate Nucleus
Cerebral Cortex (Frontal) - Superficial
Cerebral Cortex - Superficial
Cerebral Cortex (Temporal) - Superficial
Globus Pallidus
Ventral Pallidum
Hippocampus
Pons-Dorsal
Pons-Ventral
Cerebellum
Cerebellum

FIG. 21B




FIG. 21C




FIG. 21D




FIG. 22A




FIG. 22B




FIG. 23A




FIG. 23B




FIG. 23C




FIG. 23D



anti-gD - Plasma
hu37D3.v28.A4 hIgG4-S228P.YTE - Plasma
Plasma (µg/mL)
10000
1000
100
10
0
10
20
30
40
50
Days Post Dose

FIG. 23E



Plasma Total Tau Concentration,
Normalized to Baseline (%) Elecsys
10000
1000
100
10
-10
-5
0
0.5
1.0
1.5
2.0
10
20
30
40
Time (Day)
anti-gD - PD
hu37D3.v28.A4 hIgG4-S228P.YTE - PD

FIG. 24A



anti-gD - PD
hu37D3.v28.A4 hIgG4-S228P.YTE - PD
Plasma Total Tau Concentration, Normalized to Baseline (%) Elecsys
10000
1000
100
10
-10
-5
0
0.5
1.0
1.5
2.0
10
20
30
40
Time (Day)

FIG. 24B